It works by combining two medications, naltrexone and bupropion, which help to reduce hunger and control cravings, making it easier to follow a reduced-calorie diet and exercise plan
It can cause kidney and liver damage, thyroid disturbances and severe allergic reactions or infections, and has not been approved for aesthetic use by Malaysias National Pharmaceutical Regulatory Agency (NPRA), the US Food and Drug Administration or the World Health Organisation
It is a small protein made of three amino acids: cysteine, glycine, and glutamate
The STEP (Semaglutide Treatment Effect in People with Obesity) trials involved thousands of participants and demonstrated significant weight loss results while monitoring safety: Most participants experienced 15-20% weight loss over 68 weeks The safety profile was consistent with other GLP-1 receptor agonists Discontinuation rates due to adverse events were about 7% (compared to 3.1% with placebo) Trial participants maintained regular medical supervision throughout The STEP-1 trial, published in the New England Journal of Medicine, showed that semaglutide produced greater weight loss than any other FDA-approved anti-obesity medication to date, with a safety profile deemed acceptable by medical authorities
.png)
-1775582746855.png&w=3840&q=75)
